Fulgent Genetics’ oncology pivot gets sharper as FID-007 shows Phase 2 activity at ASCO 2026
Fulgent Genetics has a diagnostics base and a cancer drug signal. FID-007 now faces the tougher Phase 3 test.
What the Akeso–INOVIO immunotherapy collaboration signals for the future of glioblastoma clinical research
Akeso and INOVIO test cadonilimab plus INO-5412 in the INSIGhT glioblastoma trial. Explore what this immunotherapy strategy could mean for GBM research.